Device Trial Radar · NCT06057051
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
245
Planned (sponsor's estimate)
Start
Sep 1, 2023
Primary completion
Aug 2025
Study completion Aug 2027
Sponsor
- Lead sponsor
- Glaukos CorporationPublic (GKOS)
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
Conditions
- Glaucoma
Interventions
iStent InfiniteDevice
iStent Infinite Trabecular Micro-Bypass System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from BaselineTime frame: 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glaukos Investigator Site
Cincinnati, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.